Catalent's Acquisition by Novo Holdings Put on Hold for 30 Days for Antitrust Review
Shots:
- According to the acquisition, Catalent will receive a $16.5B all-cash payment for $63.50 per share, with a 16.5% premium to the previous closing price and a 47.5% premium to the 60-days average on Feb 2, 2024; which Reflects a strategy of investing in Life Sciences ventures
- Novo Holdings plans to sell Catalent’s 3 fill-finish sites (located in Anagni, Italy; Bloomington, Indiana, US; and Brussels, Belgium) and other related assets
- On May 6, 2024, the company announced a 30-day delay in the acquisition. The delay is attributed to FTC's antitrust scrutiny on the buyout; Acquisition completion is expected by the end of 2024
Ref: Catalent | Image: Catalent
Related News:- Novo Nordisk Reports the Acquisition of Cardior Pharmaceuticals for ~$1.11B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
